Investors revolt over pay, while BlackRock blames ‘vague’ language for underwhelming climate vote at Barclays
Round up: the latest on ESG-related resolutions
Both ISS and Glass Lewis are opposing AstraZeneca’s proposed pay package for its CEO Pascal Soriot, which, if approved, would see his potential pay soar to 900% of his reported £1.3m salary, depending on performance targets.
It is the second year in a row that the UK-based pharma…
You must have a SUBSCRIPTION or FREE TRIAL to view this PAID content.
Already got a Subscription or Free Trial?
Not got a Subscription or Free Trial?
One Free Trial per user; if your Free Trial has expired, please email firstname.lastname@example.org.